Clozapine levels lowered by modafinil: A case report and brief review of modafinil in schizophrenia

Clinical Schizophrenia and Related Psychoses

Volumn 2, Issue 1, 2008, Pages 88-90

  Fischer, Bernard A ^a   Weiner, Elaine ^a  

^a MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Clozapine; Modafinil; Pharmacokinetics; Schizophrenia

Indexed keywords

CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DOPAMINE; MODAFINIL;

ADULT; AFRICAN AMERICAN; ARTICLE; BEDTIME DOSAGE; BRAIN REGION; CASE REPORT; CIRCADIAN RHYTHM; COGNITION; DOPAMINE RELEASE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG METABOLISM; FATIGUE; HUMAN; HYPERSALIVATION; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSICAL ACTIVITY; POSITIVE END EXPIRATORY PRESSURE; SCHIZOPHRENIA; SEDATION; SLEEP APNEA SYNDROME; TREATMENT DURATION; TREATMENT OUTCOME; WAKEFULNESS;

EID: 42549123708     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.2.1.7     Document Type: Article

References (15)

1. Sandson NB, Cozza KL, Armstrong SC, Eckermann G, Fischer BA, Phillips B. Clozapine case series. Psychosomatics 2007;48(2):170-175.
2. Dequardo JR. Modafinil-associated clozapine toxicity. Am J Psychiatry 2002;159(7):1243-1244.
3. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 2002;59(3):292-293.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition. Washington (D.C.): American Psychiatric Association; 1994.
5. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42(2):123-137.
6. Provigil® (modafinil) tablets [package insert]. Frazer, PA: Cephalon, Inc.; 2007 August.
7. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67(4):554-566.
8. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 2004;27(1):38-43.
9. Makela EH, Miller K, Cutlip WD 2nd. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 2003;64(4):485-486.
10. Sevy S, Rosenthal MH, Alvir J, Meyer S, Visweswaraiah H, Gunduz-Bruce H, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005;66(7):839-843.
11. Farrow TF, Hunter MD, Haque R, Spence SA. Modafinil and unrestrained motor activity in schizophrenia: double-blind crossover placebo-controlled trial. Br J Psychiatry 2006;189:461-462.
12. Pierre JM, Peloian JH, Wirshing DA, Wirshing WC, Marder SR. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 2007;68(5):705-710.
13. Spence SA, Green RD, Wilkinson ID, Hunter MD. Modafinil modulates anterior cungulate function in chronic schizophrenia. Br J Psychiatry 2005;187:55-61.
14. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004;29:1363-1373.
15. Hunter MD, Ganesan V, Wilkinson ID, Spence SA. Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 2006;163(12):2184-2186.